Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ModCAR GRP94
- Development stage
- Preclinical
- Lead developer
- Hauul Bio
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
ModCAR GRP94 is a non-viral modular chimeric antigen receptor (CAR) cell therapy being developed by Hauul Bio for the treatment of solid cancers. Utilizing Hauul Bio's proprietary ModCAR platform, the therapy employs a modular single-chain variable fragment (scFv) fusion protein designed to recognize and bind to glucose-regulated protein 94 (GRP94, also known as endoplasmin or HSP90B1) expressed on the surface of tumor cells. This non-viral approach is designed to simplify manufacturing and enable off-the-shelf, customizable cell therapies. ModCAR GRP94 is currently in the discovery and research stage.
- Other names
- ModCAR-GRP94ModCAR-GRP-94ModCAR-GRP 94ModCARGRP94ModCARGRP-94ModCARGRP 94
02
Targets
HSP90B1 (GRP94)
Beyond the preview
Go deeper on ModCAR GRP94.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ModCAR GRP94.